{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:48:33Z","timestamp":1782175713614,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50826-2","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:35:30Z","timestamp":1777300530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective removal of soluble FLT-1 using a high-affinity DNA aptamer for potential apheresis treatment of preeclampsia"],"prefix":"10.1038","volume":"16","author":[{"given":"Kensuke","family":"Owari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haishun","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Futami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"50826_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(00)02800-2","volume":"356","author":"JJ Walker","year":"2000","unstructured":"Walker, J. J. Pre-eclampsia. Lancet 356, 1260\u20131265 (2000).","journal-title":"Lancet"},{"key":"50826_CR2","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/j.1523-1755.2005.00316.x","volume":"67","author":"SA Karumanchi","year":"2005","unstructured":"Karumanchi, S. A., Maynard, S. E., Stillman, I. E., Epstein, F. H. & Sukhatme, V. P. Preeclampsia: a renal perspective. Kidney Int. 67, 2101\u20132113 (2005).","journal-title":"Kidney Int."},{"key":"50826_CR3","doi-asserted-by":"publisher","first-page":"e0186287","DOI":"10.1371\/journal.pone.0186287","volume":"12","author":"SC Lean","year":"2017","unstructured":"Lean, S. C., Derricott, H., Jones, R. L. & Heazell, A. E. P. Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS One. 12, e0186287 (2017).","journal-title":"PLoS One"},{"key":"50826_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1471-0528.1992.tb13819.x","volume":"99","author":"JD Hutton","year":"1992","unstructured":"Hutton, J. D., James, D. K., Stirrat, G. M., Douglas, K. A. & Redman, C. W. Management of severe pre-eclampsia and eclampsia by UK consultants. Br. J. Obstet. Gynaecol. 99, 554\u2013556 (1992).","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"50826_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S0140-6736(95)91034-4","volume":"345","author":"The Eclampsia Trial Collaborative Group","year":"1995","unstructured":"The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 345, 1455\u20131463 (1995).","journal-title":"Lancet"},{"key":"50826_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0140-6736(19)31963-4","volume":"394","author":"LC Chappell","year":"2019","unstructured":"Chappell, L. C. et al. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. Lancet 394, 1181\u20131190 (2019).","journal-title":"Lancet"},{"key":"50826_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-pathol-121808-102149","volume":"5","author":"BC Young","year":"2010","unstructured":"Young, B. C., Levine, R. J. & Karumanchi, S. A. Pathogenesis of preeclampsia. Annu. Rev. Pathol. 5, 173\u2013192 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"50826_CR8","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1210\/jc.2009-0945","volume":"94","author":"JM Roberts","year":"2009","unstructured":"Roberts, J. M. & Rajakumar, A. Preeclampsia and soluble fms-like tyrosine kinase 1. J Clin. Endocrinol. Metab. 94, 2252\u20132254 (2009).","journal-title":"J Clin. Endocrinol. Metab."},{"key":"50826_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0002-9440(10)62567-9","volume":"160","author":"Y Zhou","year":"2002","unstructured":"Zhou, Y. et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 160, 1405\u20131423 (2002).","journal-title":"Am. J. Pathol."},{"key":"50826_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl. J. Med. 350, 672\u2013683 (2004).","journal-title":"N Engl. J. Med."},{"key":"50826_CR11","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1210\/jc.2002-021942","volume":"88","author":"K Koga","year":"2003","unstructured":"Koga, K. et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88, 2348\u20132351 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"50826_CR12","doi-asserted-by":"publisher","first-page":"20613","DOI":"10.1038\/s41598-021-00152-6","volume":"11","author":"M Shibuya","year":"2021","unstructured":"Shibuya, M., Matsui, H., Sasagawa, T. & Nagamatsu, T. A simple detection method for the serum sFLT1 protein in preeclampsia. Sci. Rep. 11, 20613 (2021).","journal-title":"Sci. Rep."},{"key":"50826_CR13","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/0008-5472.CAN-08-2905","volume":"69","author":"N Rahimi","year":"2009","unstructured":"Rahimi, N., Golde, T. E. & Meyer, R. D. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1\/FLT1 in leukemic cancer cells. Cancer Res. 69, 2607\u20132614 (2009).","journal-title":"Cancer Res."},{"key":"50826_CR14","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","volume":"90","author":"RL Kendall","year":"1993","unstructured":"Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U S A. 90, 10705\u201310709 (1993).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"50826_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.str.2016.12.012","volume":"25","author":"S Markovic-Mueller","year":"2017","unstructured":"Markovic-Mueller, S. et al. Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A. Structure 25, 341\u2013352 (2017).","journal-title":"Structure"},{"key":"50826_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649\u2013658 (2003).","journal-title":"J. Clin. Invest."},{"key":"50826_CR17","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers, B. F., Flyvbjerg, A. & De Vriese, A. S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 65, 2003\u20132017 (2004).","journal-title":"Kidney Int."},{"key":"50826_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler, H. et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl. J. Med. 374, 13\u201322 (2016).","journal-title":"N Engl. J. Med."},{"key":"50826_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1161\/HYPERTENSIONAHA.113.01787","volume":"63","author":"S Verlohren","year":"2014","unstructured":"Verlohren, S. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1\/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 63, 346\u2013352 (2014).","journal-title":"Hypertension"},{"key":"50826_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nbt.4297","volume":"36","author":"AA Turanov","year":"2018","unstructured":"Turanov, A. A. et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36, 1164\u20131173 (2018).","journal-title":"Nat. Biotechnol."},{"key":"50826_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.116.08408","volume":"69","author":"K Onda","year":"2017","unstructured":"Onda, K. et al. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. Hypertension 69, 457\u2013468 (2017).","journal-title":"Hypertension"},{"key":"50826_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1681\/ASN.2015020157","volume":"27","author":"R Thadhani","year":"2016","unstructured":"Thadhani, R. et al. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J. Am. Soc. Nephrol. 27, 903\u2013913 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"50826_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.preghy.2018.04.007","volume":"12","author":"K Winkler","year":"2018","unstructured":"Winkler, K. et al. Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: The Freiburg preeclampsia H.E.L.P.-Apheresis study. Pregnancy Hypertens. 12, 136\u2013143 (2018).","journal-title":"Pregnancy Hypertens."},{"key":"50826_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5414\/CNP96S18","volume":"96","author":"J Guben\u0161ek","year":"2021","unstructured":"Guben\u0161ek, J. et al. Treatment of preeclampsia at extremely preterm gestation with therapeutic plasma exchange. Clin. Nephrol. 96, 101\u2013106 (2021).","journal-title":"Clin. Nephrol."},{"key":"50826_CR25","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/j.1582-4934.2009.00820.x","volume":"14","author":"A Bergmann","year":"2010","unstructured":"Bergmann, A. et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14, 1857\u20131867 (2010).","journal-title":"J. Cell. Mol. Med."},{"key":"50826_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.bios.2012.10.026","volume":"41","author":"CH Chung","year":"2013","unstructured":"Chung, C. H., Kim, J. H., Jung, J. & Chung, B. H. Nuclease-resistant DNA aptamer on gold nanoparticles for the simultaneous detection of Pb2\u2009+\u2009and Hg2\u2009+\u2009in human serum. Biosens. Bioelectron. 41, 827\u2013832 (2013).","journal-title":"Biosens. Bioelectron."},{"key":"50826_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/346818a0","volume":"346","author":"AD Ellington","year":"1990","unstructured":"Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818\u2013822 (1990).","journal-title":"Nature"},{"key":"50826_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s10753-016-0477-1","volume":"40","author":"M Boshtam","year":"2017","unstructured":"Boshtam, M., Asgary, S., Kouhpayeh, S., Shariati, L. & Khanahmad, H. Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review. Inflammation 40, 340\u2013349 (2017).","journal-title":"Inflammation"},{"key":"50826_CR29","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1021\/ac070189y","volume":"79","author":"Z Tang","year":"2007","unstructured":"Tang, Z. et al. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 79, 4900\u20134907 (2007).","journal-title":"Anal. Chem."},{"key":"50826_CR30","doi-asserted-by":"publisher","first-page":"20979","DOI":"10.3390\/molecules201219739","volume":"20","author":"Q Zhu","year":"2015","unstructured":"Zhu, Q., Liu, G. & Kai, M. DNA Aptamers in the Diagnosis and Treatment of Human Diseases. Molecules 20, 20979\u201320997 (2015).","journal-title":"Molecules"},{"key":"50826_CR31","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1253\/circj.CJ-12-0212","volume":"76","author":"G Wallukat","year":"2012","unstructured":"Wallukat, G. et al. The first aptamer-apheresis column specifically for clearing blood of \u03b21-receptor autoantibodies. Circ. J. 76, 2449\u20132455 (2012).","journal-title":"Circ. J."},{"key":"50826_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.2200121","volume":"249","author":"C Tuerk","year":"1990","unstructured":"Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505\u2013510 (1990).","journal-title":"Science"},{"key":"50826_CR33","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1093\/nar\/gkn956","volume":"37","author":"M Kimoto","year":"2009","unstructured":"Kimoto, M., Kawai, R., Mitsui, T., Yokoyama, S. & Hirao, I. An unnatural base pair system for efficient PCR amplification and functionalization of DNA molecules. Nucleic Acids Res. 37, e14 (2009).","journal-title":"Nucleic Acids Res."},{"key":"50826_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2556","volume":"31","author":"M Kimoto","year":"2013","unstructured":"Kimoto, M., Yamashige, R., Matsunaga, K., Yokoyama, S. & Hirao, I. Generation of high-affinity DNA aptamers using an expanded genetic alphabet. Nat. Biotechnol. 31, 453\u2013457 (2013).","journal-title":"Nat. Biotechnol."},{"key":"50826_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1021\/jacs.6b10767","volume":"139","author":"K Matsunaga","year":"2017","unstructured":"Matsunaga, K., Kimoto, M. & Hirao, I. High-affinity DNA aptamer generation targeting von Willebrand factor A1-domain by genetic alphabet expansion for systematic evolution of ligands by exponential enrichment using two types of libraries composed of five different bases. J. Am. Chem. Soc. 139, 324\u2013334 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"50826_CR36","doi-asserted-by":"publisher","first-page":"18478","DOI":"10.1038\/srep18478","volume":"5","author":"K Matsunaga","year":"2015","unstructured":"Matsunaga, K. et al. Architecture of high-affinity unnatural-base DNA aptamers toward pharmaceutical applications. Sci. Rep. 5, 18478 (2015).","journal-title":"Sci. Rep."},{"key":"50826_CR37","first-page":"7487","volume":"44","author":"M Kimoto","year":"2016","unstructured":"Kimoto, M., Nakamura, M. & Hirao, I. Post-ExSELEX stabilization of an unnatural-base DNA aptamer targeting VEGF165 toward pharmaceutical applications. Nucleic Acids Res. 44, 7487\u20137494 (2016).","journal-title":"Nucleic Acids Res."},{"key":"50826_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omtn.2018.11.011","volume":"14","author":"K Futami","year":"2018","unstructured":"Futami, K., Kimoto, M., Lim, Y. W. S. & Hirao, I. Genetic alphabet expansion provides versatile specificities and activities of unnatural-base DNA aptamers targeting cancer cells. Mol. Ther. Nuc Acids. 14, 158\u2013170 (2018).","journal-title":"Mol. Ther. Nuc Acids"},{"key":"50826_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/ard.1991.1.141","volume":"1","author":"PS Eder","year":"1991","unstructured":"Eder, P. S., DeVine, R. J., Dagle, J. M. & Walder, J. A. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2019 exonuclease in plasma. Antisense Res. Dev. 1, 141\u2013151 (1991).","journal-title":"Antisense Res. Dev."},{"key":"50826_CR40","doi-asserted-by":"publisher","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","volume":"269","author":"J Waltenberger","year":"1994","unstructured":"Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. & Heldin, C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988\u201326995 (1994).","journal-title":"J. Biol. Chem."},{"key":"50826_CR41","first-page":"213","volume":"7","author":"A Sawano","year":"1996","unstructured":"Sawano, A., Takahashi, T., Yamaguchi, S., Aonuma, M. & Shibuya, M. Flt-1 but not KDR\/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell. Growth Differ. 7, 213\u2013221 (1996).","journal-title":"Cell. Growth Differ."},{"key":"50826_CR42","doi-asserted-by":"publisher","unstructured":"Howell, C. et al. Apheresis procedures for the treatment of patients and for the collection of cellular therapy products: A British Society for Haematology guideline. Transfus Med. https:\/\/doi.org\/10.1111\/tme.13144, (2025). Published online.","DOI":"10.1111\/tme.13144"},{"key":"50826_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/jca.21222","volume":"27","author":"G Lee","year":"2012","unstructured":"Lee, G. & Arepally, G. M. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J. Clin. Apher. 27, 117\u2013125 (2012).","journal-title":"J. Clin. Apher"},{"key":"50826_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10047-017-0968-3","volume":"20","author":"T Arimura","year":"2017","unstructured":"Arimura, T. et al. Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013. J. Artif. Organs. 20, 244\u2013251 (2017).","journal-title":"J. Artif. Organs"},{"key":"50826_CR45","doi-asserted-by":"crossref","unstructured":"Xin, H. et al. Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders. Proc. Natl. Acad. Sci. U S A. 118, e1921252118 (2021).","DOI":"10.1073\/pnas.1921252118"},{"key":"50826_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/v14020389","volume":"14","author":"KJ Fujimoto","year":"2022","unstructured":"Fujimoto, K. J. et al. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity. Viruses 14, 389 (2022).","journal-title":"Viruses"},{"key":"50826_CR47","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1021\/ct301097u","volume":"9","author":"Y Cho","year":"2013","unstructured":"Cho, Y. et al. Noncovalent Interactions of DNA Bases with Naphthalene and Graphene. J. Chem. Theory Comput. 9, 2090\u20132096 (2013).","journal-title":"J. Chem. Theory Comput."},{"key":"50826_CR48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50826-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:05:20Z","timestamp":1782173120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50826-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50826"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50826-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of commercially obtained human sera (normal and preeclamptic patient sera) was approved by the institutional ethics committee of TAGCyx Biotechnologies Inc. (approval nos. TCB210215, TCB250529, and TCB250711). All samples were anonymized and handled in accordance with institutional guidelines and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"19434"}}